| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUES: | ||||||||||
Total Revenues | ||||||||||
3,573 | 9,538 | 12,743 | 6,786 | - | - | - | - | - | - | - |
Product Development and Licensing Agreements | ||||||||||
- | - | - | - | 1,442 | 838 | 160 | 146 | 110 | 40,187 | 5,662 |
Contracts and Grants | ||||||||||
- | - | - | - | 4,038 | 2,748 | 1,617 | 281 | 36 | 220 | 1,802 |
Product Royalties | ||||||||||
- | - | - | - | - | - | 2,334 | 10,775 | 9,119 | 6,386 | 7,716 |
Total Revenues | ||||||||||
- | - | - | - | 5,480 | 3,586 | 4,111 | 11,202 | 9,265 | 46,793 | 15,180 |
OPERATING EXPENSES: | ||||||||||
Research and Development | ||||||||||
42,672 | 66,449 | 96,171 | 102,726 | 100,171 | 104,381 | 67,401 | 47,398 | 32,439 | 27,650 | 26,169 |
Royalty | ||||||||||
- | - | - | - | - | - | 2,334 | 10,775 | 9,119 | 12,077 | 8,397 |
Gain on Sale of Assets | ||||||||||
- | - | - | - | - | - | - | - | - | - | 604 |
General and Administrative | ||||||||||
15,426 | 19,269 | 25,003 | 35,979 | 33,837 | 20,622 | 14,805 | 10,016 | 9,193 | 10,378 | 17,119 |
Goodwill Impairment | ||||||||||
- | 90,976 | - | - | - | - | - | - | - | - | - |
Intangible Asset Impairment | ||||||||||
- | 18,677 | 13,000 | - | - | - | - | - | - | - | - |
Other Asset Impairment | ||||||||||
1,800 | - | - | - | - | - | - | - | - | - | - |
Gain on Fair Value Remeasurement of Contingent Consideration | ||||||||||
1,294 | 29,621 | 800 | - | - | - | - | - | - | - | - |
Amortization of Acquired Intangible Assets | ||||||||||
- | 224 | 896 | 997 | 1,013 | 1,013 | 1,013 | 1,090 | 1,913 | 3,143 | 949 |
Total Operating Expenses | ||||||||||
58,604 | 165,974 | 134,270 | 139,702 | 135,021 | 126,016 | 85,553 | 69,279 | 52,664 | 53,248 | 52,030 |
Operating Loss | ||||||||||
-55,031 | -156,436 | -121,527 | -132,916 | -129,541 | -122,430 | -81,442 | -58,077 | -43,399 | -6,455 | -36,850 |
Investment and Other Income, Net | ||||||||||
4,153 | 4,487 | 4,214 | 4,386 | 2,344 | 4,350 | 819 | 530 | 396 | 5,259 | - |
Investment and Other Income, Net | ||||||||||
- | - | - | - | - | - | - | - | - | - | 248 |
Interest Expense | ||||||||||
- | - | - | - | - | - | 927 | 1,576 | 1,796 | 1,337 | 452 |
Net Loss Before Income Tax Benefit | ||||||||||
-50,878 | -151,949 | -117,313 | -128,530 | -127,197 | - | - | - | - | - | -37,054 |
Income Tax Benefit | ||||||||||
- | -765 | -24,282 | - | - | - | - | - | - | - | -529 |
Net Loss | ||||||||||
-50,878 | -151,184 | -93,031 | -128,530 | -127,197 | -118,080 | -81,550 | -59,123 | -44,799 | -2,533 | -36,525 |
Basic and Diluted Net Loss Per Common Share | ||||||||||
-3.51 | -14.48 | -10.86 | -18.99 | -1.31 | -1.32 | -1.02 | -1.02 | -1.13 | -0.08 | -1.84 |
Shares Used in Calculating Basic and Diluted Net Loss per Share | ||||||||||
14,507 | 10,442 | 8,570 | 6,769 | 97,051 | 89,399 | 79,777 | 57,713 | 39,501 | 31,868 | - |
COMPREHENSIVE LOSS: | ||||||||||
Shares Used in Calculating Basic Net Loss per Share (Note 3) (in shares) | ||||||||||
- | - | - | - | - | - | - | - | - | - | 19,823 |
Shares Used in Calculating Diluted Net Loss per Share (Note 3) (in shares) | ||||||||||
- | - | - | - | - | - | - | - | - | - | 19,823 |
Net Loss | ||||||||||
-50,878 | -151,184 | -93,031 | -128,530 | -127,197 | -118,080 | -81,550 | -59,123 | -44,799 | -2,533 | -36,525 |
Other Comprehensive Income (Loss): | ||||||||||
Foreign Currency Translation Adjustments | ||||||||||
- | - | - | - | 15 | -5 | -3 | 2 | -9 | 2 | -12 |
Unrealized Gain on Marketable Securities | ||||||||||
36 | 19 | 23 | 234 | -298 | -73 | -74 | 91 | -90 | 203 | -48 |
Comprehensive Loss | ||||||||||
-50,842 | -151,165 | -93,008 | -128,296 | -127,480 | -118,158 | -81,627 | -59,030 | -44,898 | -2,328 | -36,585 |
Product Development and Licensing Agreements | ||||||||||
Total Revenues | ||||||||||
473 | 3,341 | 3,153 | 2,174 | - | - | - | - | - | - | - |
Contracts and Grants | ||||||||||
Total Revenues | ||||||||||
3,100 | 6,197 | 9,590 | 4,612 | - | - | - | - | - | - | - |